Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy

Molecular Therapy

Volumn 6, Issue 5, 2002, Pages 627-636

  Brockstedt, Dirk G ^a,b   Diagana, Melissa ^a   Zhang, Ying ^a   Tran, Kimvan ^a   Belmar, Nicole ^a   Meier, Melinda ^a   Yang, Adrienne ^a   Boissiere, Florence ^a   Lin, Augustine ^a   Chiang, Yawen ^a  

^a Aventis Gencell   (United States)

^b CERUS CORPORATION   (United States)

Author keywords

4TI mammary tumor; Adenovirus; Cytokines; Cytotoxic T lymphocytes; Gene therapy; GM CSF; HSVtk suicide gene; IL 2; Immunotherapy; Non immunogenic

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; THYMIDINE KINASE; ADENOVIRUS VECTOR; GANCICLOVIR;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE TRANSFER; GENETICS; HERPES SIMPLEX VIRUS; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; TIME; TRANSGENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CARCINOMA; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; EXCISION; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; NONHUMAN; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; SIMPLEXVIRUS;

EID: 0036853112     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0722     Document Type: Article

References (47)

1. Fidler, I. J., and Hart, I. R. (1982). Biological diversity in metastatic neoplasms: origins and implications. Science 217: 998-1003.
2. Koscielny, S., et al. (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br. J. Cancer 49: 709-715.
3. Koscielny, S., Tubiana, M., and Valleron, A. J. (1985). A simulation model of the natural history of human breast cancer. Br. J. Cancer 52: 515-524.
4. Pardoll, D. M. (1998). Cancer vaccines. Nat. Med. 4: 525-531.
5. Parmiani, G. (1998). Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s). Gene Ther. 5: 863-864.
6. Mach, N., and Dranoff, G. (2000). Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12: 571-575.
7. Dranoff, G., et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocytes-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
8. Shand, N., et al. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene 2325-2335.
9. Rainov, N. G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11: 2389-2401.
10. Moolten, F. L. (1994). Drug sensitivity ("suicide") genes for selective cancer thermotherapy. Cancer Gene Ther. 1: 279-287.
11. Moolten, F. L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a protective cancer control strategy. Cancer Res. 46: 5276-5281.
12. Freeman, S. M., et al. (1993). The "bystander effect" tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
13. Freeman. S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A. J. (1996). In situ use of suicide genes for cancer therapy. Semin. Oncol. 23: 31-45.
14. Blaese, R. M., et al. (1994). In situ delivery of suicide genes for cancer treatment. Eur. J. Cancer 30A: 1190-1193.
15. Barba, D., Hardin, J., Sadelain, M., and Gage, F. H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91: 4348-4352.
16. Caruso, M., et al. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90: 7024-7028.
17. Yuhas, J. M., Toya, R. E., and Wagner, E. (1975). Specific and nonspecific stimulation of resistence to the growth and metastasis of the line 1 lung carcinoma. Cancer Res. 35: 242-244.
18. Chen, S. H., et al. (1996). Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56: 3758-3762.
19. Golumbek, P. T., et al. (1992). Herpes simplex-1 virus thymidine kinase genes is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J. Immunother. 12 224-230.
20. Castleden, S. A., et al. (1997). A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. 8: 2087-2102.
21. Su, H., Lu, R., and Kan, Y. W. (2000). Adeno-associated viral-mediated gene transfer to hepatoma: thymide kinase/interleukin 2 is more effective in tumor killing non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther. 1: 509-515.
22. O'Malley, B. W., Jr., et al. (1997). The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol. Endocrinol. 11: 667-673.
23. Okada, H., et al. (1999). Effective cytokine gene therapy against an intracranial using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 6: 219-226.
24. Sharma, S., et al. (1997). Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther. 4: 1361-1370.
25. Santodonato, L., et al. (1997). Local and systemic antitumor response after combined therapy of metastatic tumors with tumor cells expressing IFN-α and HSVtk: perspectives for the generation of cancer vaccines. Gene Ther. 4: 1246-1255.
26. Bonnekoh, B., et al. (1998). Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B 16 melanoma model. J. Invest. Dermatol. 110: 867-871.
27. Majumdar, A. S., et al. (2000). Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 7: 1086-1099.
28. Brockstedt, D. G., et al. (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92: 67-75.
29. Falo, L. D., Jr., Kovacsovics-Bankowski, M., Thompson, K., and Rock, K. L. (1995). Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1: 649-653.
30. Schmidt, W., et al. (1995). Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92: 4711-4714.
31. Armstrong, C. A., et al. (1996). Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56: 2191-2198.
32. Hall, S. J., Sanford, M. A., Atkinson, G., and Chen, S. H., (1998). Induction of potent anti-tumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58: 3221-3225.
33. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. (1997). Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801-810.
34. Tsuge, T., Yamakawa, M., and Tsukamoto, M. (2000). Infiltrating dendritic/Langerhans cells in primary breast cancer. Breast Cancer Res. Treat. 59: 141-152.
35. Kielian, T., Nagai, E., Ikubo, A., Rasmussen, C. A., and Suzuki, T. (1999). Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1 α and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol. Immunother. 48: 123-131.
36. Tazi, A., et al (1993). Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J. Clin. Invest. 91: 566-576.
37. Galluci, S., Lolkema, M., and Matzinger, P. (1999). Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
38. Sauter, B., et al. (2000). Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191: 423-434.
39. Lee, K. H., et al. (1998). Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161: 4183-4194.
40. Kim, D. W., Harada, T., Saito, I., and Miyamura, T. (1993). An efficient expression vector for stable expression in human liver cells. Gene 134: 307-308.
41. Crouzet, J., et al. (1997). Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad. Sci. USA 94: 1414-1419.
42. Jung, T., Schauer, U., Heusser, C., Neumann, C., and Rieger, C. (1993). Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159: 197-207.
43. Tsai, S. C., Gansbacher, B., Tait, L., Miller, F. R., and Heppner, G. H. (1993). Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. 85: 546-553.
44. Aslakson, C. J., and Miller, F. R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
45. Yuhas, J. M., Pazmino, N. H., and Wagner, E. (1975). Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma. Cancer Res. 35: 237-241.
46. Heitjan, D. F., Manni, A., and Santen, R. J. (1993). Statistical analysis of in vivo tumor growth experiments. Cancer Res. 53: 6042-6050.
47. Murali-Krishna, K., et al. (1998). In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystanders activation in primary and secondary responses to viral infection. Adv. Exp. Med. Biol. 452: 123-142.